New Agent May Offer Cardiac Benefits in CKD Patients

Share this content:

A new agent called sitaxentan, which blocks endothelin-1 receptors, may lower novel risk factors in patients with chronic kidney disease (CKD). John Schieszer reports in today's Medical Minute that this agent and others in this class may provide important heart-related benefits for CKD patients.
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters